Literature DB >> 1522218

Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

R A Roubey1, C W Pratt, J P Buyon, J B Winfield.   

Abstract

It has been reported that antiphospholipid autoantibodies do not recognize phospholipid alone, but rather the plasma protein beta 2-glycoprotein I (beta 2GPI), or a beta 2GPI-phospholipid complex. In vitro beta 2GPI binds to anionic phospholipids and inhibits the prothrombinase activity of procoagulant membranes. In light of the fact that lupus anticoagulants, a type of antiphospholipid antibody, have similar anticoagulant properties, the relationship of beta 2GPI to lupus anticoagulant activity was investigated. IgG from patients with autoimmune diseases or syphilis were tested for anticardiolipin reactivity and lupus anticoagulant activity in the presence and absence of beta 2GPI. As expected, anti-cardiolipin reactivity associated with autoimmune disease was beta 2GPI dependent. In contrast, IgG from a patient with syphilis recognized cardiolipin alone and binding was inhibited by beta 2GPI. Autoimmune antiphospholipid antibodies prolonged the dilute Russell viper venom time of normal plasma, but had no effect on beta 2GPI-depleted plasma. Antiphospholipid antibodies associated with syphilis had no anticoagulant effect. RP-1, an anti-beta 2GPI mAb, had anticoagulant effects similar to those of autoimmune antiphospholipid antibodies. These data demonstrate that antiphospholipid autoantibodies exert lupus anticoagulant activity via an interaction with beta 2GPI. These antibodies and RP-1 appear to amplify the anticoagulant effect of beta 2GPI itself.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1522218      PMCID: PMC329970          DOI: 10.1172/JCI115926

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant.

Authors:  E Marciniak; E H Romond
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

2.  [Genetic studies on the deficiency of beta 2-glycoprotein I of human serum].

Authors:  H Cleve
Journal:  Humangenetik       Date:  1968

3.  Investigations on the genetics and population genetics of the beta 2-glycoprotein I polymorphism.

Authors:  A L Koppe; H Walter; V P Chopra; M Bajatzadeh
Journal:  Humangenetik       Date:  1970

4.  Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column.

Authors:  T Exner; N Sahman; B Trudinger
Journal:  Biochem Biophys Res Commun       Date:  1988-09-15       Impact factor: 3.575

Review 5.  Lupus anticoagulants.

Authors:  S S Shapiro; P Thiagarajan
Journal:  Prog Hemost Thromb       Date:  1982

6.  Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant.

Authors:  S C Lo; H H Salem; M A Howard; M J Oldmeadow; B G Firkin
Journal:  Br J Haematol       Date:  1990-11       Impact factor: 6.998

7.  beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.

Authors:  I Schousboe
Journal:  Blood       Date:  1985-11       Impact factor: 22.113

8.  Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics.

Authors:  H P McNeil; C N Chesterman; S A Krilis
Journal:  Br J Haematol       Date:  1989-12       Impact factor: 6.998

9.  Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.

Authors:  E M Bevers; M Galli; T Barbui; P Comfurius; R F Zwaal
Journal:  Thromb Haemost       Date:  1991-12-02       Impact factor: 5.249

10.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

View more
  28 in total

Review 1.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 3.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  Anti-beta 2-glycoprotein I antibodies.

Authors:  J Arvieux; J C Bensa; B Roussel; M G Colomb
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 5.  Anti-beta 2-glycoprotein I antibodies and thrombosis.

Authors:  J P Viard; Z Amoura; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 6.  Heterogeneity of antiphospholipid antibodies and their cofactors.

Authors:  M C Boffa; M Berard; M Karmochkine
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

7.  Evaluation of serum anti-cardiolipin antibodies after non-surgical periodontal treatment in chronic periodontitis patients.

Authors:  Farin Kiany; Azita Hedayati
Journal:  Odontology       Date:  2014-02-14       Impact factor: 2.634

8.  beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin.

Authors:  S K Moestrup; I Schousboe; C Jacobsen; J R Leheste; E I Christensen; T E Willnow
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 9.  Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.

Authors:  G Girardi; N Mackman
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

10.  Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity.

Authors:  R Rolla; M Vidali; R Serino; P Pergolini; E Albano; G Bellomo
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.